Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

236.80 +1.13 (+0.48%)

Delayed Quote Updated: 11:55 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval ↗

October 26, 2022

A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals...

Via Benzinga

Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline ↗

October 21, 2022

Via Benzinga

Why Zymeworks Stock Is Soaring Today ↗

October 19, 2022

Investors applauded a major licensing deal with Jazz Pharmaceuticals.

Via The Motley Fool

Why Is Zymeworks (ZYME) Stock Up Today? ↗

October 19, 2022

Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ).

Via InvestorPlace

Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal ↗

October 19, 2022

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Jazz Pharmaceuticals' Return On Capital Employed Insights ↗

August 08, 2022

Via Benzinga

'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst ↗

August 05, 2022

Via Benzinga

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 18, 2022

These two durable companies can navigate the market downturn and beyond.

Via The Motley Fool

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

October 13, 2022

Investors are betting on these companies' revenue growth prospects.

Via The Motley Fool

3 Top Marijuana Stocks to Buy for the Long Haul ↗

October 07, 2022

The three have the financial strength to benefit from increased cannabis sales and cannabis therapies.

Via The Motley Fool

3 Stocks Savvy Investors Are Buying Hand Over Fist ↗

October 06, 2022

These high-flying stocks are defying the bear market.

Via The Motley Fool

Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit ↗

September 29, 2022

A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision...

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

August 04, 2022

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Via Benzinga

UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar ↗

September 29, 2022

Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading.

Via Benzinga

5 Analysts Have This to Say About Jazz Pharmaceuticals ↗

September 21, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q4 ↗

September 15, 2022

A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Via InvestorPlace

The Bright Future Of Cannabis Isn’t In Dispensaries - It’s In The Biotech Lab ↗

August 29, 2022

Cannabis businesses offer a lucrative opportunity for investors, but one sector in particular represents untapped potential: cannabinoid pharmaceuticals.

Via Talk Markets

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures ↗

August 18, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents...

Via Benzinga

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

Via Investor Brand Network

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...

Via FinancialNewsMedia

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread ↗

July 15, 2022

The company just hired three new executives, likely putting a buyout in the rearview.

Via Investor's Business Daily

Cannabis Stocks Struggle Through Q2 2022 ↗

July 15, 2022

An overview of how cannabis stocks fared in Q2 and what investors should understand about the space.

Via Talk Markets

Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study ↗

July 11, 2022

Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

Via Benzinga

Brazilian Fund Invests $19M In US Cannabis Stocks ↗

July 05, 2022

As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are...

Via Benzinga

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder ↗

June 29, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea...

Via Benzinga

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint ↗

June 28, 2022

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.